Spotlight Innovation Inc. (fka STLT)

[bow-tie]

Dr. Greggory Laff: http://www.spotlightinnovation.com/press-releases/spotlight-innovation-appoints-dr-geoffrey-laff-as-vice-president-of-scientific-strategy/

Dr. Laff, who joined Spotlight in July, is responsible for STLT’s R&D strategy, evaluation of new potential acquisitions and will assist with clinical management. He brings ~20 years of experience in drug development, biotechnology, drug research and healthcare-related investment. His industry work has largely focused on oncology and immunotherapy - Spotlight’s therapeutic focus area – and has involved advising large pharma including Pfizer (PFE), Bristol-Myers Squibb (BMY), Sanofi (SNY) and Boehringer Ingelheim. Dr’ Laff’s full bio (from STLT’s July 14th press release is below).

Dr. Laff is a life sciences industry veteran with nearly 20 years of experience in healthcare venture capital, public equity investment, biotechnology, drug development, market research, and medical communications. Specializing in oncology and immunology, he has advised leading pharmaceutical companies including Pfizer, Bristol-Myers Squibb, Sanofi and Boehringer Ingelheim.